Eurofins Expands Presence in Indian Pharmaceutical Market With New State-of-the-Art Hyderabad Campus
January 18 2023 - 12:15AM
Business Wire
Regulatory News:
Eurofins Scientific SE (Paris:ERF):
Eurofins Scientific (EUFI.PA), the global leader in food,
environment, pharmaceutical and cosmetic product testing and a
global scientific leader in bioanalytical testing, announces the
acquisition of assets to establish a fully-equipped,
state-of-the-art laboratory campus in Genome Valley, Hyderabad. The
acquisition includes a facility capable of supporting large global
and Indian pharmaceutical clients as well as small biotech
companies in the areas of synthetic organic chemistry, analytical
R&D, bioanalytical services (for both large and small
molecules), in-vivo pharmacology, safety toxicology and formulation
R&D. The state-of-the-art laboratories occupy over 90,000
ft2.
The announcement was made after Minister Mr KT Rama Rao’s
meeting with Eurofins management at the World Economic Forum in
Davos. Mr Jayesh Ranjan IAS, Principal Secretary, Industries and
Commerce Department and Mr Shakthi M Nagappan, Director
Lifesciences, Government of Telangana were also present during the
meeting.
With this investment through its subsidiary Eurofins Advinus,
the Eurofins network now has a significant campus in Hyderabad that
complements its existing operations in India with additional
capacity in discovery chemistry, analytical chemistry and
bioanalytical services. The investment will also allow Eurofins
Advinus to extend its service offering to deliver formulation
development as well as in-vitro and in-vivo biology capabilities
from early 2023.
Hyderabad is regarded as the epicentre of drug discovery and
development services in Asia, while Genome Valley is India’s first
organised cluster for Life Sciences R&D and Clean Manufacturing
activities, with world-class infrastructure facilities in the form
of Industrial / Knowledge Parks, Special Economic Zones (SEZs),
multi-tenanted dry and wet laboratories and incubation facilities.
Genome Valley is home to more than 200 companies with a scientific
workforce of about 15,000 professionals, working for industry
leaders in global and Indian pharmaceuticals. This investment by
Eurofins Advinus further reinforces the position of Hyderabad as a
world class location for drug discovery.
Comment from Dr Gilles Martin, Eurofins CEO: “Eurofins is
committed to long-term investments to grow our globally leading
laboratory network. Given the importance of India in global
pharmaceutical R&D value chains, we are very excited about our
new Hyderabad campus so we can better serve this important centre
for pharmaceutical development and innovation.”
Comment from Honorable Minister, Mr K.T. Rama Rao: “I am
delighted to announce the entry of Eurofins in Hyderabad and Genome
Valley. I am extremely thrilled to note that the company has
ambitious growth plans from this facility. With this investment,
Eurofins joins an illustrious list of global companies in Genome
Valley. The Telangana Government is committed to supporting
Eurofins and their plans.”
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. Eurofins is the global leader in
food, environment, pharmaceutical and cosmetic product testing, and
in discovery pharmacology, forensics, advanced material sciences
and agroscience Contract Research services. Eurofins is also a
market leader in certain testing and laboratory services for
genomics, and in the support of clinical studies, as well as in
BioPharma Contract Development and Manufacturing. The Group also
has a rapidly developing presence in highly specialised and
molecular clinical diagnostic testing and in-vitro diagnostic
products.
With over 61,000 staff across a decentralised and
entrepreneurial network of 940 laboratories in 59 countries,
Eurofins offers a portfolio of over 200,000 analytical methods to
evaluate the safety, identity, composition, authenticity, origin,
traceability and purity of a wide range of products, as well as
providing innovative clinical diagnostic testing services and
in-vitro diagnostic products.
The Group’s objective is to provide its customers with
high-quality services, innovative solutions and accurate results on
time. Eurofins is ideally positioned to support its clients’
increasingly stringent quality and safety standards and the
increasing demands of regulatory authorities as well as the
requirements of healthcare practitioners around the world.
In 2020 and 2021, Eurofins reacted quickly to meet the global
challenge of COVID-19, by creating the capacity to help over 20
million patients monthly who may have been impacted by the pandemic
with our testing products and our services and directly supporting
healthcare professionals working on the front line to fight the
virus. The Group has established widespread PCR testing
capabilities and has carried out over 40 million tests in its own
laboratories, is supporting the development of a number of vaccines
and has established its SAFER@WORK™ testing, monitoring and
consulting programmes to help ensure safer environments, travel and
events during COVID-19.
Eurofins has grown very strongly since its inception and its
strategy is to continue expanding its technology portfolio and its
geographic reach. Through R&D and acquisitions, the Group draws
on the latest developments in the field of biotechnology and
analytical chemistry to offer its clients unique analytical
solutions.
Shares in Eurofins Scientific are listed on the Euronext Paris
Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF
FP).
Until it has been lawfully made public widely by Eurofins
through approved distribution channels, this document contains
inside information for the purpose of Regulation (EU) 596/2014 of
the European Parliament and of the Council of 16 April 2014 on
market abuse, as amended.
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgment of
Eurofins Scientific’s management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantees can be made as to their completeness
or validity.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230117006028/en/
For more information, please visit www.eurofins.com or
contact: Investor Relations Eurofins Scientific SE Phone: +32 2
766 1620 E-mail: ir@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jul 2023 to Jul 2024